Compare Stocks: EBS, JNJ, MAZE, and VIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$5.07 +5.2%	$7.11	$4.36 ▼ $14.06	$260.47M	2.35	1.36 million shs	1.42 million shs
JNJ Johnson & Johnson	$270.69 +1.2%	$255.08	$173.33 ▼ $276.47	$651.25B	0.24	7.00 million shs	6.18 million shs
MAZE Maze Therapeutics	$29.43 +1.7%	$28.31	$12.91 ▼ $53.65	$1.63B	2.21	356,530 shs	280,573 shs
VIR Vir Biotechnology	$9.78 +6.2%	$9.41	$4.35 ▼ $11.66	$1.65B	1.66	1.48 million shs	1.76 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	0.00%	+10.58%	-32.45%	-40.25%	-45.07%
JNJ Johnson & Johnson	0.00%	+3.94%	+4.38%	+15.35%	+51.57%
MAZE Maze Therapeutics	0.00%	+8.28%	+6.28%	+14.16%	+118.32%
VIR Vir Biotechnology	0.00%	+5.84%	+4.71%	+6.42%	+124.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$5.07 +5.2%	$7.11	$4.36 ▼ $14.06	$260.47M	2.35	1.36 million shs	1.42 million shs
JNJ Johnson & Johnson	$270.69 +1.2%	$255.08	$173.33 ▼ $276.47	$651.25B	0.24	7.00 million shs	6.18 million shs
MAZE Maze Therapeutics	$29.43 +1.7%	$28.31	$12.91 ▼ $53.65	$1.63B	2.21	356,530 shs	280,573 shs
VIR Vir Biotechnology	$9.78 +6.2%	$9.41	$4.35 ▼ $11.66	$1.65B	1.66	1.48 million shs	1.76 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	0.00%	+10.58%	-32.45%	-40.25%	-45.07%
JNJ Johnson & Johnson	0.00%	+3.94%	+4.38%	+15.35%	+51.57%
MAZE Maze Therapeutics	0.00%	+8.28%	+6.28%	+14.16%	+118.32%
VIR Vir Biotechnology	0.00%	+5.84%	+4.71%	+6.42%	+124.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	2.17	Hold	$10.00	97.24% Upside
JNJ Johnson & Johnson	2.80	Moderate Buy	$268.22	-0.91% Downside
MAZE Maze Therapeutics	3.00	Buy	$66.00	124.26% Upside
VIR Vir Biotechnology	2.89	Moderate Buy	$20.63	110.89% Upside

Current Analyst Ratings Breakdown

Latest EBS, JNJ, MAZE, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/21/2026	EBS Emergent Biosolutions	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight
8/12/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
8/11/2026	EBS Emergent Biosolutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $10.00
8/7/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/6/2026	VIR Vir Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
8/6/2026	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$270.00 ➝ $287.00
8/3/2026	JNJ Johnson & Johnson	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$280.00
8/3/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$742.90M	0.35	$3.65 per share	1.39	$6.66 per share	0.76
JNJ Johnson & Johnson	$94.19B	6.93	$14.14 per share	19.14	$35.26 per share	7.68
MAZE Maze Therapeutics	$167.50M	9.76	N/A	N/A	$8.16 per share	3.61
VIR Vir Biotechnology	$68.56M	24.14	N/A	N/A	$5.81 per share	1.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	18.11	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.63	31.37	21.15	2.58	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	11/4/2026 (Estimated)

Latest EBS, JNJ, MAZE, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.36	1.98%	+5.25%	62.11%	64 Years
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Latest EBS, JNJ, MAZE, and VIR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.17%	8/25/2026	8/25/2026	9/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.70	5.42	2.95
JNJ Johnson & Johnson	0.44	1.09	0.81
MAZE Maze Therapeutics	0.09	18.31	18.31
VIR Vir Biotechnology	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
JNJ Johnson & Johnson	69.55%
MAZE Maze Therapeutics	N/A
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	6.00%
JNJ Johnson & Johnson	0.16%
MAZE Maze Therapeutics	5.30%
VIR Vir Biotechnology	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	51.27 million	48.20 million	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
MAZE Maze Therapeutics	121	55.55 million	52.61 million	N/A
VIR Vir Biotechnology	580	169.22 million	164.31 million	Optionable

EBS, JNJ, MAZE, and VIR Headlines

Recent News About These Companies

Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum

August 20 at 11:49 PM | theglobeandmail.com

Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst

August 19, 2026 | tipranks.com

Q3 EPS Estimate for Vir Biotechnology Reduced by Analyst

August 14, 2026 | americanbankingnews.com

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

Equities Analysts Offer Predictions for VIR Q3 Earnings

August 12, 2026 | marketbeat.com

Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities

August 12, 2026 | theglobeandmail.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

Evercore ISI Sticks to Its Buy Rating for Vir Biotechnology (VIR)

August 9, 2026 | theglobeandmail.com

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary

August 7, 2026 | finance.yahoo.com

Vir outlines ECLIPSE 1 top-line in Q4 2026 while projecting cash runway into the second half of 2028

August 6, 2026 | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Vir Biotechnology Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

August 5, 2026 | zacks.com

Vir Biotechnology (VIR) Releases Q2 2026 Earnings: Revenue and EPS Beat Estimates

August 5, 2026 | quiverquant.comQ

Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

August 5, 2026 | marketbeat.com

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 5, 2026 | businesswire.com

Renaissance Technologies LLC Increases Stake in Vir Biotechnology, Inc. $VIR

August 5, 2026 | marketbeat.com

Public Employees Retirement System of Ohio Acquires Shares of 112,700 Vir Biotechnology, Inc. $VIR

August 4, 2026 | marketbeat.com

950,000 Shares in Vir Biotechnology, Inc. $VIR Bought by Avidity Partners Management LP

August 1, 2026 | marketbeat.com

Vir Biotechnology (VIR) Expected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EBS, JNJ, MAZE, and VIR Company Descriptions

Emergent Biosolutions NYSE:EBS

$5.07 +0.25 (+5.19%)

As of 08/21/2026 03:58 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Johnson & Johnson NYSE:JNJ

$270.69 +3.32 (+1.24%)

As of 08/21/2026 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Maze Therapeutics NASDAQ:MAZE

$29.43 +0.50 (+1.73%)

As of 08/21/2026 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Vir Biotechnology NASDAQ:VIR

$9.78 +0.57 (+6.19%)

As of 08/21/2026 04:00 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EBS, JNJ, MAZE, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EBS, JNJ, MAZE, and VIR Earnings

Compare Dividends

Latest EBS, JNJ, MAZE, and VIR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EBS, JNJ, MAZE, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EBS, JNJ, MAZE, and VIR Company Descriptions

Emergent Biosolutions NYSE:EBS

Johnson & Johnson NYSE:JNJ

Maze Therapeutics NASDAQ:MAZE

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools